Fragment BioTech
Fragment Bio is developing a rapid biosensing technology that detects molecular fragments—such as DNA, RNA, or protein fragments—to screen for cancers, pathogens, and contaminants. The platform is designed for portability and point-of-care integration, with results benchmarked against gold-standard assays to ensure accuracy. This approach aims to shift biomarker testing from centralized labs to faster, more accessible settings.
- Biotechnology
- Healthcare Technology
- Medical Devices
- Hardware
- Artificial Intelligence
Funding
Founders
Founder details are not available yet.
Product
Problem
Traditional biomarker detection for cancer, pathogen, and contaminant screening typically requires laboratory-based equipment, lengthy processing times, and specialized personnel, limiting rapid and accessible testing. This constrains early detection efforts and delays actionable diagnostic information, particularly in point-of-care or resource-limited settings.
Solution
Fragment Bio is developing an innovative biosensing technology that detects molecular fragments—such as DNA, RNA, or protein fragments—as biomarkers for a wide range of conditions, including cancers, pathogens, and environmental contaminants. The platform is designed to deliver rapid results while being carefully benchmarked against current gold-standard methods to ensure accuracy and reliability. By measuring these fragment-based biomarkers with a novel sensing approach, the company aims to shift biomarker data collection toward faster, more portable, and more accessible formats. The technology is positioned to drive a disruptive shift in capability, access, and precision of biomarker data for screening and diagnostics outside traditional laboratory environments.
Target Audience
Primary customers include clinical diagnostics providers, hospitals, and point-of-care testing developers seeking rapid biomarker screening solutions, as well as public health and environmental monitoring organizations needing on-site contaminant or pathogen detection.
Features
- Fragment-based biomarker detection technology capable of identifying cancers, pathogens, and contaminants
- Sensing platform engineered for portability and wearable or point-of-care integration, reducing reliance on centralized lab infrastructure
- Rapid measurement capability designed to accelerate time-to-result compared with conventional diagnostic workflows
- Benchmarking against established gold-standard assays to validate accuracy and clinical relevance
- Versatile application across multiple biomarker classes, including genomics and virology use cases